342617-07-6

Basic information

• Product Name: 4-HYDROXY-6-IODOQUINOLINE
• Synonyms: 4-HYDROXY-6-IODOQUINOLINE;6-IODOQUINOLIN-4(1H)-ONE;6-IODOQUINOLIN-4-OL;BUTTPARK 100\01-54;4-Hyrdroxy-6-iodoquinoline;6-Iodo-4-quinolinol;6-iodo-1H-quinolin-4-one
• CAS NO: 342617-07-6
• Molecular Formula: C₉H₆INO
• Molecular Weight: 271.05
• Mol File: 342617-07-6.mol

Chemical Properties

• Boiling Point: 394℃
• Flash Point: 192℃
• Appearance: /
• Density: 1.974
• Vapor Pressure: 7.15E-05mmHg at 25°C
• Refractive Index: 1.679
• Storage Temp.: 2-8°C(protect from light)
• PKA: 3.85±0.40(Predicted)
• CAS DataBase Reference: 4-HYDROXY-6-IODOQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-HYDROXY-6-IODOQUINOLINE(342617-07-6)
• EPA Substance Registry System: 4-HYDROXY-6-IODOQUINOLINE(342617-07-6)

Safety Data

• Hazardous Substances Data: 342617-07-6(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
4-HYDROXY-6-IODOQUINOLINE is used as a reagent in organic synthesis for its unique structural features, including the presence of a hydroxyl and iodine atom, which facilitate various chemical reactions and the formation of new compounds.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 4-HYDROXY-6-IODOQUINOLINE serves as a valuable compound for drug discovery. Its unique properties allow it to be a potential candidate for the development of new medications, particularly in the areas of medicinal chemistry where its structure can be further modified to target specific biological pathways or diseases.
Used in Medicinal Chemistry:
4-HYDROXY-6-IODOQUINOLINE is utilized in medicinal chemistry as a building block for the synthesis of other organic compounds with potential therapeutic applications. Its structural attributes, including the hydroxyl and iodine functionalities, make it a suitable starting material for the creation of novel pharmaceutical agents.
While the provided materials do not specify particular applications in different industries, the general uses outlined above cover the broad potential of 4-HYDROXY-6-IODOQUINOLINE in chemical and pharmaceutical fields. If more specific applications are identified in the future, they can be added to the list accordingly.

InChI:InChI=1/C9H6INO/c10-6-1-2-8-7(5-6)9(12)3-4-11-8/h1-5H,(H,11,12)

Upstream product

• 302949-02-6 4-hydroxy-6-iodoquinoline-3-carboxylic acid 
• 540-37-4 p-aminoiodobenzene 
• 909344-69-0 5-{[(4-iodophenyl)amino]methylidene}-2,2-dimethyl-1,3-dioxane-4,6-dione 

Downstream Products

• 40107-07-1 4-chloro-6-iodo-quinoline 
• 1912423-48-3 4-chloro-6-(isopropylthio)quinoline 
• 1219101-03-7 4-chloro-6-quinolinesulfonyl chloride 
• 1062590-01-5 3-[(6-iodo-4-quinolinyl)amino]-4-methylphenol 
• 1032816-36-6 C₉H₅BrINO 

Relevant articles and documents

A Selective and Orally Bioavailable Quinoline-6-Carbonitrile-Based Inhibitor of CDK8/19 Mediator Kinase with Tumor-Enriched Pharmacokinetics

Senexins are potent and selective quinazoline inhibitors of CDK8/19 Mediator kinases. To improve their potency and metabolic stability, quinoline-based derivatives were designed through a structure-guided strategy based on the simulated drug–target dockin

QUINOLINE-BASED COMPOUNDS AND METHODS OF INHIBITING CDK8/19

Disclosed herein are quinoline-based compounds and method for inhibiting CDK8 or CDK19 for the intervention in diseases, disorders, and conditions. The quinoline-based composition comprise substituents at quinoline ring positions 4 and 6, wherein the substituent at position 4 is selected from a substituted or unsubstituted arylalkylamine or a substituted or unsubstituted arylhetrocyclylamine. Pharmaceutical compositions comprising the substituted qunioline compositions, methods of inhibiting CDK8 or CDK19, and methods of treating CDK8/19-associated diseases, disorders, or conditions are also disclosed.

Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel

RIP2 kinase was recently identified as a therapeutic target for a variety of autoimmune diseases. We have reported previously a selective 4-aminoquinoline-based RIP2 inhibitor GSK583 and demonstrated its effectiveness in blocking downstream NOD2 signaling in cellular models, rodent in vivo models, and human ex vivo disease models. While this tool compound was valuable in validating the biological pathway, it suffered from activity at the hERG ion channel and a poor PK/PD profile thereby limiting progression of this analog. Herein, we detail our efforts to improve both this off-target liability as well as the PK/PD profile of this series of inhibitors through modulation of lipophilicity and strengthening hinge binding ability. These efforts have led to inhibitor 7, which possesses high binding affinity for the ATP pocket of RIP2 (IC50 = 1 nM) and inhibition of downstream cytokine production in human whole blood (IC50 = 10 nM) with reduced hERG activity (14 μM).

The Identification and Pharmacological Characterization of 6-(tert-Butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of RIP2 Kinase

RIP2 kinase is a central component of the innate immune system and enables downstream signaling following activation of the pattern recognition receptors NOD1 and NOD2, leading to the production of inflammatory cytokines. Recently, several inhibitors of R

AMINO-QUINOLINES AS KINASE INHIBITORS

Disclosed are quinoline compounds having the formula: wherein R1, R2 and A are as defined herein, and methods of making and using the same.

QUINOLYL AMINES AS KINASE INHIBITORS

Disclosed are compounds having the formula: wherein R1, R2, R3, R4 and R5 are as defined herein, and methods of making and using the same.

Controlled derivatization of polyhalogenated quinolines utilizing selective cross-coupling reactions

Straightforward procedures for the derivatization of tri- and tetrahalogenated quinolines utilizing sequential selective Pd-catalyzed cross-coupling reactions are described. Taking advantage of intrinsic halide reactivity, substrate control, and appropria

NOVEL QUINOLINE DERIVATIVES

The invention relates to compounds represented by Formula (I): and to pharmaceutically acceptable salts or solvates of said compounds, wherein each of A, R3-8, X3, X5, m, and n are defined herein. The invention also relates to pharmaceutical compositions containing the compounds of Formula (I) and to methods of treating hyperproliferative disorders in a mammal by administering compounds of Formula (I).